Enbezotinib

DB21565InvestigationalSmall molecule

Enbezotinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Enbezotinib is a tyrosine kinase inhibitor. Enbezotinib is under investigation in clinical... Enbezotinib is under investigation in clinical trial NCT04161391 (Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations).

Mechanism: Pharmacologically active on Proto-oncogene tyrosine-protein kinase Src and RET proto-oncogene
Curator reviewed
Formula / weight: C₂₁H₂₁FN₆O₃ · 424.436 g/mol (avg)
Code names: TPX-0046

Resolves to

Compound

UNIIF6EVK907XRCAS2359649-81-1ChEMBLCHEMBL5095062

Structure

InChIKeyBYYQDEOVMILBQT-XZJROXQQSA-NSMILES[H][C@]12CCC[C@@]1([H])N1CC3=C(O[C@@H](C)CNC(=O)C4=C5N=C1C(O2)=CN5N=C4)N=CC(F)=C3

Targets

P12931SRCO43519RET

What you can answer from here — as of September 21, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Enbezotinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account